Article Text

other Versions

Download PDFPDF
Systematic review with meta-analysis
Statins in patients with CKD prove beneficial in reducing cardiovascular events and mortality but show no benefit in patients on dialysis
  1. Sandeep Krishnan,
  2. Terry A Jacobson
  1. Department of Medicine, Emory University, Atlanta, Georgia, USA
  1. Correspondence to: Dr Terry A Jacobson
    Department of Medicine, Emory University, Atlanta, GA 30303, USA; tjaco02{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on:


High-quality evidence suggests that chronic kidney disease (CKD) should now be considered a coronary heart disease (CHD) risk equivalent. Although statin therapy consistently reduces coronary events in the general population, the clinical benefits of lipid lowering in persons with CKD are less certain. Although multiple studies have shown possible benefit from statin therapy in early-stage CKD patients, there has been a recent concern that patients with more severe CKD, such as those on dialysis, do not seem to benefit.


The authors identified randomised controlled trials with statins from a previously published meta-analysis,1 and supplemented it with recent trials identified in EMBASE, the Cochrane Central Register of Controlled Trials and the Cochrane Renal Group's Specialised …

View Full Text


  • Competing interests None.